All Stories

  1. Intranasal immunization protects against Acinetobacter baumannii-associated pneumonia in mice
  2. The structure of the polysaccharide isolated from Acinetobacter baumannii strain LAC-4
  3. Serum resistance, gallium nitrate tolerance and extrapulmonary dissemination are linked to heme consumption in a bacteremic strain of Acinetobacter baumannii
  4. Pentavalent Single-Domain Antibodies Reduce Campylobacter jejuni Motility and Colonization in Chickens
  5. Parametric estimation for the scale parameter for scale distributions using moving extremes ranked set sampling
  6. A Mouse Model of Acinetobacter baumannii-Associated Pneumonia Using a Clinically Isolated Hypervirulent Strain
  7. Correlates of protection following vaccination of mice with gene deletion mutants of Francisella tularensis subspecies tularensis strain, SCHU S4 that elicit varying degrees of immunity to systemic and respiratory challenge with wild-type bacteria
  8. Profiling of Cytokine and Chemokine Responses Using Multiplex Bead Array Technology
  9. Design and immunological properties of Helicobacter pylori glycoconjugates based on a truncated lipopolysaccharide lacking Lewis antigen and comprising an α-1,6-glucan chain
  10. Chemical Synthesis and Immunological Evaluation of the Inner Core Oligosaccharide of Francisella tularensis
  11. Role of Macrophages in Early Host Resistance to Respiratory Acinetobacter baumannii Infection
  12. BALB/c mice, but not C57BL/6 mice immunized with a ΔclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: Association of protection with post-vaccination and post-challenge immu...
  13. Simultaneous analysis of cardiolipin and lipid A from Helicobacter pylori by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
  14. c-di-GMP protects against intranasal Acinetobacter baumannii infection in mice by chemokine induction and enhanced neutrophil recruitment
  15. Acinetobacter baumannii Infection Inhibits Airway Eosinophilia and Lung Pathology in a Mouse Model of Allergic Asthma
  16. Role of neutrophils and NADPH phagocyte oxidase in host defense against respiratory infection with virulent Francisella tularensis in mice
  17. Infection of Mice with Francisella as an Immunological Model
  18. Intranasal Immunization with an Archaeal Lipid Mucosal Vaccine Adjuvant and Delivery Formulation Protects against a Respiratory Pathogen Challenge
  19. ChemInform Abstract: 3′,5′‐Cyclic Diguanylic Acid: A Small Nucleotide that Makes Big Impacts
  20. Molecular Immune Responses to Aerosol Challenge with Francisella tularensis in Mice Inoculated with Live Vaccine Candidates of Varying Efficacy
  21. Methylamidation for Sialoglycomics by MALDI-MS: A Facile Derivatization Strategy for Both α2,3- and α2,6-Linked Sialic Acids
  22. Recent advances in the development of novel mucosal adjuvants and antigen delivery systems
  23. Archaeal lipid mucosal vaccine adjuvant and delivery system
  24. The potential of 3′,5′-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant
  25. Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: Effects of host background and route of immunization
  26. 3′,5′-Cyclic diguanylic acid: a small nucleotide that makes big impacts
  27. Pentabody-mediated antigen delivery induces antigen-specific mucosal immune response
  28. 6th Annual Vaccines: All Things Considered
  29. The structure of the polysaccharide O-chain of the LPS from Acinetobacter baumannii strain ATCC 17961
  30. Non-antibiotic strategies for the prevention/treatment ofClostridium difficileinfection
  31. Synthesis and immunostimulatory properties of the phosphorothioate analogues of cdiGMP
  32. Safety of Intranasally Administered Archaeal Lipid Mucosal Vaccine Adjuvant and Delivery (AMVAD) Vaccine in Mice
  33. M cell-targeted delivery of vaccines and therapeutics
  34. Molecular immunology of experimental primary tularemia in mice infected by respiratory or intradermal routes with type A Francisella tularensis
  35. Lymphotoxin‐α Plays Only a Minor Role in Host Resistance to Respiratory Infection with Virulent Type A Francisella tularensis in Mice
  36. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines
  37. A novel pentamer versus pentamer approach to generating neutralizers of verotoxin 1
  38. Vaccines and therapeutic agents for tularemia
  39. Virulence comparison in mice of distinct isolates of type A Francisella tularensis
  40. Archaeosomes as Drug and Vaccine Nanodelivery Systems
  41. Low dose aerosol infection of mice with virulent type A Francisella tularensis induces severe thymus atrophy and CD4+CD8+ thymocyte depletion
  42. Archaeosome Immunostimulatory Vaccine Delivery System
  43. Therapeutic potential of microbes and microbial products in the management of human allergic asthma
  44. Toll-like receptor 4 (TLR4) does not confer a resistance advantage on mice against low-dose aerosol infection with virulent type A Francisella tularensis
  45. Mice sublethally infected with Francisella novicida U112 develop only marginal protective immunity against systemic or aerosol challenge with virulent type A or B strains of F. tularensis
  46. Susceptibility of immunodeficient mice to aerosol and systemic infection with virulent strains of Francisella tularensis
  47. Susceptibility of various mouse strains to systemically- or aerosol-initiated tularemia by virulent type A Francisella tularensis before and after immunization with the attenuated live vaccine strain of the pathogen
  48. Archaeosomes as Adjuvants for Combination Vaccines
  49. Novel cancer vaccines: an update
  50. Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies
  51. Activation of the mucosal immune system in irritable bowel syndrome
  52. Development of a Dendritic Cell (DC) Vaccine for Advanced Colorectal Cancer
  53. Cryptosporidium parvum in intestinal mucosal biopsies from patients with inflammatory bowel disease
  54. Novel cancer vaccines
  55. Reduced colonization of gastric mucosa by Helicobacter pylori in mice deficient in interleukin‐101
  56. Serum proinflammatory cytokine response in patients with advanced liver tumors following selective internal radiation therapy (SIRT) with 90Yttrium microspheres
  57. Inhibition of mitogen‐induced murine lymphocyte proliferation by Helicobacter pylori cell‐free extract
  58. Novel anti-Helicobacter pylori agents
  59. Dendritic cell‐based cancer immunotherapy: Potential for treatment of colorectal cancer?
  60. Rapid elimination of Helicobacter pylori and reduction of histocompatibility leucocyte antigen‐DR expression 12 h after a single dose of omeprazole, amoxycillin and metronidazole triple therapy
  61. The intestinal microflora and inflammatory bowel disease
  62. Experimental induction of pneumonia in mice with Bordetella parapertussis isolated from sheep
  63. Pneumonia in lambs inoculated withBordetella parapertussis: Clinical and pathological studies